Factors affecting circadian variability

Blood Pressure Monitoring

Volumn 5, Issue SUPPL. 1, 2000, Pages

  Giles, Thomas D ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Angiotensin II; Angiotensin II receptor; Blood pressure; Cardiovascular disease; Circadian rhythm; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; RENIN; SODIUM CHLORIDE; WATER;

ADRENERGIC TRANSMISSION; AROUSAL; BLOOD CLOTTING; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; HEART INFARCTION; HEART RATE; HOMEOSTASIS; HUMAN; HYPERTENSION; ISCHEMIA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; SUDDEN DEATH; TARGET ORGAN; THROMBOCYTE AGGREGATION;

EID: 0033947181     PISSN: 13595237     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126097-200005001-00002     Document Type: Review

References (42)

1. 1 Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79:733-743.
2. 2 Quyyumi AA. Circadian rhythms in cardiovascular disease. Am Heart J 1990; 120:726-733.
3. 3 Manfredini R, Gallerani M, Portaluppi R, Fersini C. Relationships of the circadian rhythm of thrombotic, ischemic, hemorrhagic, and arrhythmic events to blood pressure rhythms. Ann NY Acad Sci 1996; 783:141-158.
4. 4 Neutel JM, Smith DHG. The circadian pattern of blood pressure: cardiovascular risk and therapeutic opportunities. Curr Opin Nephrol Hypertens 1997; 6:250-256.
5. 5 Stroth U, Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol 1999; 33 (suppl 1):S21-S28.
6. 6 Zitnay C, Siragy HM. Action of angiotensin receptor subtypes on the renal tubules and vasculature: implications for volume homeostasis and atherosclerosis. Miner Electrolyte Metab 1998; 24:362-370.
7. 7 Unger T, Culman J, Gohlke P. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens 1998; 16 (suppl 7):S3-S9.
8. 8 Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313:1315-1322.
9. 9 Kelly-Hayes M, Wolf PA, Kase CS, Brand FN, McGurk JM, D'Agostino RB. Temporal patterns of stroke onset. The Framingham Study. Stroke 1995; 26:1343-1347.
10. 10 Willich SN, Levy D, Rocco MB, Tofler GH, Stone PH, Muller JE. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987; 60:801-806.
11. 11 Mulcahy D, Keegan J, Cunningham D, Quyyumi A, Crean P, Park A, et al. Circadian variation of total ischaemic burden and its alteration with anti-anginal agents. Lancet 1988; 2:755-759.
12. 12 Anwar YA, White WB. Chronotherapeutics for cardiovascular disease. Drugs 1998; 55:631-643.
13. 13 Deedwania PC, Nelson JR. Hemodynamic evaluation by simulataneous electrocardiographic and blood pressure monitoring. Circulation 1990; 82:1296-1304.
14. 14 Quyyumi AA, Panza JA, Diodati JG, Lakatos E, Epstein SE. Circadian variation in ischemic threshold: a mechanism underlying the circadian variation in ischemic events. Circulation 1992; 86:22-28.
15. 15 Panza JA, Epstein SE, Quyyumi AA. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med 1991; 325:986-990.
16. 16 Smolensky MH, Bing ML. Chronobiology and Chronotherapeutics in primary care: patient care. Clinical Focus 1997; (suppl):1-15.
17. 17 Dodt C, Breckling U, Derad I, Fehm HL, Born J. Plasma epinephrine and norepinephrine concentrations of healthy humans associated with nighttime sleep and morning arousal. Hypertension 1997; 30:71-76.
18. 18 Portaluppi F, Bagni B, Uberti E, Montanari L, Cavallini R, Transforini G, et al. Circadian rhythms of atrial natriuretic peptide, renin, aldosterone, cortisol, blood pressure and heart rate in normal and hypertensive subjects. J Hypertens 1990; 8:85-95.
19. 19 Pickering TG, James GD, Determinants and consequences of the diurnal rhythm of blood pressure. Am J Hypertens 1993; 6:166S-169S.
20. 20 Brezinski DA, Tofler GH, Muller JE, Pohjola-Sintonen S, Willich SN, Schafer AI, et al. Morning increase in platelet aggregability. Association with assumption of the upright posture. Circulation 1988; 78:35-40.
21. 21 Andreotti F, Davies GJ, Hackett DR, Khan MI, De Bart ACW, Aber VR, et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988; 62:635-637
22. 22 Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91:1269-1281.
23. 23 Johnstone CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346:1403-1407.
24. 24 Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45:205-251.
25. 25 Dendorfer A, Raasch W, Tempel K, Dominak P. Interactions between the renin-angiotensin system (RAS) and the sympathetic system. Basic Res Cardiol 1998; 93 (suppl 2):24-29.
26. 26 Taddei S, Virdis A, Mattei P, Duranti P, Favilla S, Salvetti A. Vascular renin-angiotensin system and sympathetic nervous system activity in human hypertension. J Cardiovasc Pharmacol 1994; 23 (suppl 1):S9-S14.
27. 27 Swedberg KB. Impact of neuroendocrine activation on coronary artery disease. Am J Cardiol 1998; 82:8H-14H.
28. 28 Mehta JL. Modulation of arterial thrombosis by angiotensin-converting enzyme inhibition and angiotensin II type 1-receptor blockade. Am J Cardiol 1998; 82 (suppl 10A):53S-56S.
29. 29 Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95:995-1001.
30. 30 Swartz SI, Moore TJ. Effect of angiotensin II on collagen-induced platelet activation in normotensive subjects. Thromb Haemost 1990; 63:87-90.
31. 31 Chung O, Csikos T, Unger T. Angiotensin II receptor pharmacology and AT, receptor blockers. J Hum Hypertens 1999; 13 (suppl 1):S11-S20.
32. 32 Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999; 33:613-621.
33. 33 Alderman MH, Madhavan S, Ooi WL, Cohen WL, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
34. 34 Kala R, Fyhrquist F, Eisalo A. Diurnal variation of plasma angiotensin II in man. Scand J Clin Lab Invest 1973; 31:363-365.
35. 35 Peters RW, Muller JE, Goldstein S, Byington R, Friedman LM. Propranolol and the morning increase in the frequency of sudden cardiac death (BHAT Study). Am J Cardiol 1989; 63:1518-1520.
36. 36 Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421 : angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982; 4:966-972.
37. 37 Ambrose J, Pribnow DG, Giraud GD, Perkins KD, Muldoon L, Greenberg BH. Angiotensin type I receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle. J Cardiovasc Pharmacol 1999; 33:433-439.
38. 38 Richer C, Fornes P, Cazaubon C, Domergue V, Nisato D, Giudicelli JF. Effects of long-term angiotensin II AT, receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. Cardiovasc Res 1999; 41:100-108.
39. 39 Goodfield NE, Newby DE, Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99:2983-2985.
40. 40 Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747-752.
41. 41 Pitt B, Konstam MA. Overview of angiotensin II-receptor antagonists. Am J Cardiol 1998; 82 (suppl 10A):47S-49S.
42. 42 Lacourcière Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998; 3:295-302.